Transgene Biotek Limited reported a standalone net loss of ₹38.90 lakh for the quarter ended June 30, 2026 (Q1FY27), a narrowing from the ₹43.37 lakh loss recorded in the same period last year. The improvement was primarily driven by a 21.2% year-on-year increase in revenue from operations to ₹6.00 lakh and a substantial reduction in other expenses. Despite the operational gains, finance costs remained elevated at ₹28.95 lakh, continuing to pressure profitability. The Board of Directors approved the unaudited financial results and the limited review report on August 7, 2026.

The company’s total income stood at ₹6.00 lakh, as other income was nil, contrasting with ₹14.99 lakh recorded in the preceding quarter (Q4FY26). Total expenses decreased significantly to ₹44.90 lakh from ₹66.13 lakh in Q4FY26. This decline was largely attributable to a drop in other expenses from ₹30.09 lakh to ₹8.45 lakh. However, finance costs increased to ₹28.95 lakh from ₹27.68 lakh in the previous quarter. Basic earnings per share showed a loss of ₹0.05, an improvement from the loss of ₹0.06 in both the prior quarter and the corresponding period last year.

Financial Performance Overview

The consolidated financial results mirrored the standalone figures, with identical revenue, expense, and loss metrics. The subsidiary, Transgene Biotek HK Ltd, contributed zero revenue and zero net loss for the quarter. M/s. Vasavi & Co., the independent auditor, issued a limited review report confirming that the financial statements disclosed all required information under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Governance and Regulatory Updates

During its meeting on August 7, 2026, the Board appointed M/s. Manisha Dubey & Associates as Internal Auditors for the financial year 2026-27. Ms. Manisha Dubey, a peer-reviewed Chartered Accountant with over 24 years of experience, will lead the firm’s engagement. The Board also approved the extension of the Annual General Meeting (AGM) for the financial year 2025-26, subject to approval from the Registrar of Companies.

Several legal and regulatory matters remain pending. The Securities Appellate Tribunal (SAT) has adjourned its hearing to August 17, 2026. The Appellate Tribunal (Enforcement Directorate), New Delhi, heard arguments on July 23, 2026, and adjourned the matter to September 10, 2026. Additionally, the National Company Law Tribunal (NCLT) adjourned its hearing to September 23, 2026. In the matter involving Nitin Didwania, an order passed on July 8, 2026, directed the payment of ₹92.99 lakh with 6% interest; the company has filed an appeal at the Bombay High Court Commercial Division.

What the Numbers Show

The primary driver behind the narrowed loss in Q1FY27 was a substantial reduction in other expenses, which fell from ₹30.09 lakh in Q4FY26 to ₹8.45 lakh in Q1FY27. This decline offset the steady increase in finance costs, which rose to ₹28.95 lakh. While revenue growth is positive, it remains insufficient to cover the high fixed costs, particularly finance charges, which accounted for nearly 65% of total expenses. The absence of other income in Q1FY27, compared to ₹14.99 lakh in the previous quarter, highlights the volatility in non-operating revenues, making operational cost control critical for future profitability improvements.

Transgene presented positive preclinical data for its TG-MVA vaccine candidate at the World Congress on Infectious Diseases (WCID) 2026, demonstrating robust protection against mpox comparable to approved reference vaccines. The data, presented in an oral session, highlights the candidate's potential to address global supply gaps for mpox and smallpox vaccines through a scalable cell-line manufacturing process. This development is significant for biosecurity and pandemic preparedness, particularly given the limited number of current manufacturers.

The TG-MVA candidate utilizes a non-replicating MVA backbone and an innovative cell-line-based manufacturing process. This method aims to overcome industrial limitations associated with Chicken Embryo Fibroblast (CEF) manufacturing, enabling scalable and reproducible production. By leveraging innovations from its myvac platform, Transgene intends to position itself as an additional supplier for mpox and smallpox vaccines in the medium term.

Preclinical evaluations in mice and non-human primate (NHP) models showed that TG-MVA provides strong protection against severe mpox morbidity and mortality. Survival rates were identical to the reference vaccine, with 100% in mouse models and 87% in primate models. The candidate also induced broad humoral and cellular immune responses, including T-cell immunity, with neutralizing antibody levels comparable to the approved reference MVA vaccine.

Alessandro Riva, MD, Chairman and CEO of Transgene, emphasized the strategic opportunity to leverage existing investments in the MVA cell-line platform. He stated that the promising results support the rapid advancement of TG-MVA toward clinical development, with plans to implement next steps in alignment with Health Authorities. The company maintains its financial visibility until early 2028 while pursuing this initiative alongside its core therapeutic vaccine platform.

The oral presentation, titled "Robust Protection Against Monkeypox Virus Mediated by a Novel Cell-Line–Derived MVA Vaccine (TG-MVA CL)," was delivered by Nathalie Silvestre, Head of the Vectorology Laboratory at Transgene. The company remains focused on its individualized therapeutic vaccine platform myvac while expanding into preventive vaccines for Orthopoxvirus infections.